Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
MARA Rating Insight Since 2020, assets averaging a 3.1 Cost-Effectiveness score sailed through HTA evaluations, while those at just 1.96 were far more likely rejected. That 1.14-point gap often determines whether payers call your
Market Access Professionals: Your Definitive HTA Checklist for a Smooth P&R Journey Use this checklist as a self-assessment tool to ensure your dossier covers all critical evidence domains. Simply run
Every payer’s checklist is different. MARA Rating Insight Since 2020, assets with an average Clinical Effectiveness score of 3.1 sailed through HTA evaluations, while those averaging just 2.7 were more often rejected. That 0.4-point
Over the past five years, almost half of drug launches have fallen short of their sales forecasts due to misjudged pricing and reimbursement (P & R) risks, resulting in significant